- Raw materials
- Barbiturates
- Vinbarbital
Vinbarbital API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Vinbarbital | CAS No: 125-42-8 | GMP-certified suppliers
A medication that acts as a central nervous system depressant within barbiturate classes, primarily used experimentally as a hypnotic and sedative for CNS-related research applications.
Therapeutic categories
Product Snapshot
- Vinbarbital is an oral barbiturate small molecule formulation
- It is primarily investigated for use as a central nervous system depressant
- The compound is currently in experimental status with no approved regulatory market authorizations
Clinical Overview
Vinbarbital’s therapeutic indication and pharmacodynamic profile remain unspecified, and it is currently designated for experimental use. Consequently, detailed information regarding its clinical application, pharmacological effects, and precise mechanism of action has not been established or disclosed in the scientific literature.
Barbiturates typically exert their CNS depressant effects by enhancing the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) activity at GABA-A receptors, leading to increased neuronal inhibition. While vinbarbital is presumed to share this general mechanism due to its chemical class, specific mechanistic data are not available.
Pharmacokinetic parameters including absorption, distribution, metabolism, and excretion for vinbarbital have not been published. Similarly, safety and toxicity profiles, including potential adverse effects and contraindications, have not been documented, limiting comprehensive assessment of its clinical risk-benefit profile.
Notably, vinbarbital has not received regulatory approval for clinical use and is primarily of interest in research contexts. There are no widely recognized branded formulations or marketed products containing vinbarbital.
For API sourcing and quality assurance, it is essential to procure vinbarbital from suppliers with validated purity and compliance with relevant pharmacopeial standards or Good Manufacturing Practice (GMP) guidelines. Given its experimental status, thorough analytical characterization, traceability, and documentation are critical to support research integrity and regulatory compliance.
Identification & chemistry
| Generic name | Vinbarbital |
|---|---|
| Molecule type | Small molecule |
| CAS | 125-42-8 |
| UNII | 7NZH2C1T6O |
| DrugBank ID | DB13377 |
Formulation & handling
- Vinbarbital is a small molecule barbiturate with moderate lipophilicity suitable for oral formulation.
- The compound exhibits limited aqueous solubility, which may require solubilization strategies for oral dosage forms.
- No specific peptide or biologic stability concerns are anticipated, but moisture protection is recommended during handling.
Regulatory status
Vinbarbital is a type of Barbiturates
Barbiturates are a category of pharmaceutical active pharmaceutical ingredients (APIs) that have sedative, hypnotic, and anticonvulsant properties. They belong to the class of drugs called depressants, which slow down the central nervous system (CNS) activity. Barbiturates have been widely used in the medical field for their ability to induce sleep, reduce anxiety, and control seizures.
The mechanism of action of barbiturates involves enhancing the effects of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) in the brain. GABA inhibits the transmission of signals between nerve cells, leading to relaxation and sedation. Barbiturates bind to specific GABA receptors, increasing the inhibitory effects of GABA and resulting in a calming effect on the CNS.
In the past, barbiturates were commonly prescribed for insomnia, anxiety disorders, and epilepsy. However, their use has decreased significantly due to the emergence of safer and more effective alternatives with fewer side effects. Nonetheless, barbiturates are still utilized in certain medical situations, such as anesthesia induction, emergency seizure control, and in some cases of refractory epilepsy.
Despite their therapeutic benefits, barbiturates carry potential risks and side effects. They can cause drowsiness, impaired coordination, and dependence when used for extended periods. Overdose of barbiturates can be life-threatening, leading to respiratory depression and coma.
In conclusion, barbiturates are a class of API widely known for their sedative, hypnotic, and anticonvulsant properties. While their use has diminished over time, they remain important in specific medical contexts. Proper caution and medical supervision are crucial when using barbiturates to ensure safety and efficacy.
